Trump Administration’s Kidney Care National Plan

The Trump administration introduced the Kidney Care National Plan aimed at addressing deficiencies in kidney care. The Department of Health and Human Services (HHS) noted these issues contribute to high costs and low-quality care.

Market Competition and Reform

The plan seeks to increase competition in treatment markets previously dominated by DaVita Inc. and Fresenius Medical Care. Together, these companies account for about 74 percent of the market. The initiative also aims to reform the kidney transplant system, addressing the long waiting list of approximately 90,000 individuals. Many wait three to five years for a donor kidney.

Transplant System Improvement

HHS plans to implement a National Transplant Expansion Strategy, enhancing the existing framework from a 2019 executive order. This approach aims to facilitate living donations, improving access for those needing transplants.

Focus on Preventive Care

The initiative emphasizes early detection and intervention in kidney disease. By advancing treatments, the goal is to halt or slow disease progression. An estimated 37 million American adults suffer from kidney disease, although many are unaware until significant damage has occurred.

Addressing Government Involvement

HHS identified government overreach as contributing to systemic failures. Particularly, the federal role in funding end-stage renal disease care is seen as a barrier. The plan suggests government should limit its involvement to promoting accountability, competition, and innovation. Federal intervention is advised only when market failures hinder private sector solutions.